Expression analysis of BCL2L12, a new member of apoptosis-related genes, in colon cancer

Mathioudaki, Konstantina; Scorilas, Andreas; Παπαδοκωστοπούλου, Αλεξάνδρα; Xynopoulos, Dimitris; Arnogianaki, N.; Agnanti, Niki; Talieri, Maroulio

doi:10.1515/bc.2004.101

Cited by 33 publications

(25 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…27 A recent study also showed that NPC patients with BCL2L12 mRNA-positive tumors have remarkably shorter disease-free survival than those with BCL2L12 mRNAnegative tumors. 28 More recently, Papageorgious et al (2011) 29 also reported an unfavorable prognostic value of BCL2L12 in chronic lymphocytic leukemia in terms of overall survival, which implies an anti-apoptotic role of BCL2L12.…”

Section: Discussionmentioning

confidence: 97%

GSK3β regulates Bcl2L12 and Bcl2L12A anti-apoptosis signaling in glioblastoma and is inhibited by LiCl

Chou

Chou²,

Lin³

et al. 2012

Cell Cycle

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

GSK3β regulates Bcl2L12 and Bcl2L12A anti-apoptosis signaling in glioblastoma and is inhibited by LiCl

Chou

Chou²,

Lin³

et al. 2012

Cell Cycle

View full text Add to dashboard Cite

“…It is worth mentioning that an association between BCL2L12 and BCL2 mRNA expression has been noticed in breast tumors (45). In addition, we previously reported that expression of BCL2L12-A, an alternative transcript of BCL2L12, appears to be of importance in colon cancer, since it is associated with Dukes' stage and lymph node status (49). Remarkable modulations of BCL2L12 mRNA levels have also been observed in HL-60 (50-54) and SHI-1 (55) leukemia cells, MCF7 breast adenocarcinoma cells (56,57), OVCAR-3 ovary adenocarcinoma cells (58), AGS (59) and SGC7901 (60) gastric cancer cells, after treatment with various antineoplastic agents.…”

Section: Discussionmentioning

confidence: 92%

BCL2L12 is a Novel Biomarker for the Prediction of Short-Term Relapse in Nasopharyngeal Carcinoma

Fendri

Kontos

Khabir

et al. 2010

Mol Med

Self Cite

View full text Add to dashboard Cite

BCL2-like 12 (BCL2L12 ) is a new member of the apoptosis-related BCL2 gene family, members of which are implicated in various malignancies. Nasopharyngeal carcinoma is a highly metastatic, malignant epithelial tumor, with a high prevalence in Southeast Asia and North Africa. The purpose of the current study was to quantify and investigate the expression levels of the BCL2L12 gene in nasopharyngeal carcinoma biopsies and to assess its prognostic value. Total RNA was isolated from 89 malignant and hyperplastic nasopharyngeal biopsies from Tunisian patients. After testing the quality of the extracted RNA, cDNA was prepared by reverse transcription. A highly sensitive real-time polymerase chain reaction (PCR) method for BCL2L12 mRNA quantification was developed using SYBR ® Green chemistry. GAPDH served as a reference gene. Relative quantification analysis was performed using the comparative C T (2 -ΔΔCT ) method. Higher BCL2L12 mRNA levels were detected in undifferentiated carcinomas of the nasopharynx, rather than in nonkeratinizing nasopharyngeal tumors (P = 0.045). BCL2L12 expression status was also found to be positively associated with the presence of distant metastases (P = 0.014). Kaplan-Meier survival analysis demonstrated that patients with BCL2L12-positive nasopharyngeal tumors have significantly shorter disease-free survival (P = 0.020). Cox regression analysis showed BCL2L12 expression to be an unfavorable and independent prognostic indicator of short-term relapse in nasopharyngeal carcinoma (P = 0.042). Our results suggest that mRNA expression of BCL2L12 may constitute a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma.

show abstract

“…Hence, novel prognostic markers are needed to stratify patients into treatment groups. Analysis of BCL2L12 mRNA expression revealed that both splicing variants of this apoptosis-related gene are overexpressed in colon cancer samples as compared to their paired normal mucosa [46,47]. Furthermore, expression of BCL2L12-A, the alternative transcript of BCL2L12, is associated with Dukes' stage and lymph node status [46], whereas higher expression of the full-length BCL2L12 variant is associated with less aggressive forms of intestinal cancer [47].…”

Section: Discussionmentioning

confidence: 99%

The Novel Member of the BCL2 Gene Family, BCL2L12, Is Substantially Elevated in Chronic Lymphocytic Leukemia Patients, Supporting Its Value As a Significant Biomarker

et al. 2011

Self Cite

View full text Add to dashboard Cite

BCL2L12 is a recently identified gene belonging to the BCL2 family, members of which are implicated in hematologic malignancies, including chronic lymphocytic leukemia (CLL). The aim of this study was to analyze the mRNA expression of the novel apoptosis-related gene BCL2L12 in patients with CLL and to examine its prognostic and predictive value and potential clinical application as a novel molecular biomarker for CLL. For this purpose, total RNA was isolated from peripheral blood of 65 CLL patients and 23 healthy donors. An ultrasensitive quantitative real-time polymerase chain reaction methodology for BCL2L12 and BCL2 mRNA quantification was developed using SYBR Green chemistry. After preparing cDNA by reverse transcription, relative quantification analysis was performed using the comparative C T (2 ؊⌬⌬CT ) method. Furthermore, analysis of IGHV mutational status, CD38 expression, and detection of early apoptosis by double staining with Annexin V-FITC and propidium iodide were performed. According to our findings, BCL2L12 mRNA expression is significantly higher in CLL patients than in healthy donors. Receiver operating characteristic analysis demonstrated that BCL2L12 expression had significant discriminatory value, distinguishing very efficiently CLL patients from the non-leukemic population. Moreover, BCL2L12 expression predicts the presence of CLL, as demonstrated by both univariate and multivariate logistic regression analyses. Finally, high BCL2L12 mRNA levels are associated with advanced clinical stage and predict shorter overall survival in CLL patients.

show abstract

Expression analysis of BCL2L12, a new member of apoptosis-related genes, in colon cancer

Cited by 33 publications

References 14 publications

GSK3β regulates Bcl2L12 and Bcl2L12A anti-apoptosis signaling in glioblastoma and is inhibited by LiCl

GSK3β regulates Bcl2L12 and Bcl2L12A anti-apoptosis signaling in glioblastoma and is inhibited by LiCl

BCL2L12 is a Novel Biomarker for the Prediction of Short-Term Relapse in Nasopharyngeal Carcinoma

The Novel Member of the BCL2 Gene Family, BCL2L12, Is Substantially Elevated in Chronic Lymphocytic Leukemia Patients, Supporting Its Value As a Significant Biomarker

Contact Info

Product

Resources

About